Target indication Focus on selling to CNS overdose and high-burden neuropsychiatric disorder stakeholders by highlighting Solvonis Therapeutics' priority areas: Alcohol Use Disorder and PTSD, where market size and unmet need are substantial.

Clinical-stage leverage Position partnerships and funding discussions around the company’s clinical-stage status and pipeline with repurposed and novel compounds, emphasizing collaboration potential with CROs, trial networks, and early-access programs.

Investor outreach Capitalize on recent investor-facing activity and US investor reach by coordinating research coverage, analyst briefings, and sponsor-led investor days to broaden visibility among buy-side firms and strategic partners.

Strategic partnerships Propose services and collaborations with market access, commercialization planning, and numerical health economics outcomes to help bring their therapies to market efficiently, leveraging Water Tower Research’s newly signed engagement and existing investor relations.

Competitive positioning Differentiate Solvonis by underscoring its focus on acute, durable CNS interventions rather than chronic maintenance therapies, aligning BD pitches with unique value propositions for payers, providers, and patients seeking transformative treatments.